Just published in the New England Journal of Medicine

Fremanezumab, given monthly or quarterly, cuts headache frequency in chronic migraine

Prophylactic, subcutaneous fremanezumab, given monthly or quarterly, significantly reduces the number of monthly headache days in patients with chronic migraine, according to a phase 3 trial.

Read the full report here »

For more details on the trial design click here »

STRIVE study: erenumab once monthly reduces the impact of episodic migraine

Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduces migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over six months.

Read the full report here »

For more details on the trial design click here »

For an editorial comment and discussion on CGRP - the next frontier for migraine, go to: http://www.nejm.org/doi/full/10.1056/NEJMe1712559